טוען...
Fine tuning chemotherapy to match BRCA1 status
Targeted cancer therapies have been primarily directed at inhibiting oncogenes that are overexpressed or constitutively active in tumors. It is thought that as the cell’s circuitry gets rewired by the constitutive activation of some pathways it becomes exquisitely dependent on this activity. Tumor c...
שמור ב:
| Main Authors: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2925507/ https://ncbi.nlm.nih.gov/pubmed/20510205 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2010.05.015 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|